Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day

Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day

    Arpita Dutt headshot

    Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update

    Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

      Mark Vickery headshot

      Apple Sells Fewer iPhones, Gilead Misses Sales

      Apple, Inc. (AAPL) shares are falling more than 1% in after-market trading following its fiscal Q2 earnings report.

        Madeleine Johnson headshot

        Gilead (GILD) Misses Q1 Earnings and Revenue Estimates, Stock Drops

        Gilead Sciences (GILD) just released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion.

          Radius Health (RDUS) Q1 Earnings: What's in Store?

          Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3.

            What's in Store for Zoetis (ZTS) Stock This Earnings Season?

            Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.

              What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?

              Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.

                Geron (GERN) Q1 Earnings: What's in Store for the Stock?

                Geron Corporation (GERN) is expected to report first-quarter 2017 results next week

                  Apple, Facebook and Gilead Sciences are part of Zacks Earnings Preview

                  Apple, Facebook and Gilead Sciences are part of Zacks Earnings Preview

                    Is Intercept (ICPT) Poised for a Beat This Earnings Season?

                    Is Intercept (ICPT) Poised for a Beat this Earnings Season?

                      What to Expect from Keryx (KERX) Stock This Earnings Season?

                      Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.

                        Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

                        Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

                          Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

                          Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased

                            Why Gilead (GILD) Might Surprise This Earnings Season

                            Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                              Sheraz Mian headshot

                              The Tech Sector's Strong Earnings Power

                              Technology sector's Q1 results are coming from a diverse cross-section of companies.

                                BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?

                                We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                                  United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

                                  United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017

                                    What to Expect from Prothena (PRTA) This Earnings Season?

                                    Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.

                                      What's in Store for Merck (MRK) this Earnings Season?

                                      Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.

                                        Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?

                                        Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.

                                          What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?

                                          Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

                                            Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

                                              Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?

                                              Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.

                                                Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

                                                Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

                                                  Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

                                                  Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.